On January 5, 2024, Aimed Alliance submitted a comment on the Medicare Program Contract Year 2025 proposal. The comment expressed concerns regarding CMS’ proposed decision to automatically permit plans to switch consumers from a biologic to a biosimilar, irrespective of the drug’s interchangeability designation. Read the comment here.
Last Updated on February 7, 2024 by Aimed Alliance
